Trial intelligence / Profile preview

CheckMate 722: Nivolumab combinations in EGFR-mutated NSCLC

NCT02864251Phase 3

Key facts

Status: Completed
Start: Mar 2017
Primary completion: Jan 2022
Countries: 10
Sponsor: Bristol Myers Squibb
Modality: Monoclonal Antibodies

Drugs: nivolumab
Conditions: non-small cell lung cancer (NSCLC)

Overview

Phase 3, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression Free Survival at 58 months. Started Mar 2017; status: completed.

Design

3 arms

Study design: RandomizedOpen-label

Nivolumab + Chemotherapy
Nivolumab + Pemetrexed + Platinum
Nivolumab + Ipilimumab
Nivolumab + Ipilimumab
Chemotherapy
Pemetrexed + Platinum

Who it enrols

Patients with Stage IV/Recurrent EGFR-mutated NSCLC who failed 1L or 2L EGFR TKI. Excludes T790M+ after 1st/2nd gen TKI (unless failed Osimertinib). Excludes ALK+.

Endpoints

Primary

Progression Free Survival58 months

Secondary

Overall Survival67 months
Objective Response Rate67 months
Duration of Response67 months
9 Month Progression Free Survival Rate9 months
12 Month Progression Free Survival Rate12 months

Results

Not all primary endpoints met

Beyond the preview

Go deeper on NCT02864251.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02864251.